Burnaby, BC, August 21, 2023--Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. Cash and cash equivalents and marketable securities were $652.2 million as of June 30, 2023.
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 1996 | Revenues: $15.60 Million
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Burnaby, BC, August 10, 2023--Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, announced two new appointments to its Board of Directors: Dr. Gillian M. Cannon and Mr. Justin Gover.
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 1996 | Revenues: $15.60 Million
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Burnaby, BC, May 30, 2022--Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 1996 | Revenues: $15.60 Million
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Burnaby, BC, March 4, 2022--Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, reported financial results for the year ended December 31, 2021 and provided a corporate update.
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 1996 | Revenues: $15.60 Million
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Burnaby, BC, November 29, 2021--Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 1996 | Revenues: $15.60 Million
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Burnaby, BC, July 13, 2021--Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, provided an update on its ongoing XEN1101 Phase 2b "X-TOLE" clinical trial, announcing that randomization of 326 patients was completed in late June. Based on completion of patient randomization, Xenon anticipates topline results from the Phase 2b X-TOLE clinical trial in late September to mid-October 2021.
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 1996 | Revenues: $15.60 Million
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Burnaby, BC, June 7, 2021--Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, provided a corporate update following its 2021 Annual Meeting of Shareholders held on June 3, 2021.
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 1996 | Revenues: $15.60 Million
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Burnaby, BC, March 23, 2021--Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, has announced a collaboration with the Icahn School of Medicine at Mount Sinai (Mount Sinai) to facilitate an investigator-sponsored Phase 2 proof-of-concept, randomized, parallel-arm, placebo-controlled clinical trial of XEN1101 for the treatment of major depressive disorder (MDD) and anhedonia, which is an inability to feel pleasure.
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 1996 | Revenues: $15.60 Million
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Burnaby, BC, March 2, 2021--Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, reported financial results for the year ended December 31, 2020 and provided a corporate update.
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 1996 | Revenues: $15.60 Million
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Burnaby, BC, January 19, 2021--Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a neurology-focused biopharmaceutical company, outlined its key milestone opportunities and plans for a leadership transition in 2021, with all changes anticipated to take effect in June 2021 at the time of the Company's annual meeting of shareholders.
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 1996 | Revenues: $15.60 Million
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.